Prolonged vasodilatory response to nanoencapsulated sildenafil in pulmonary hypertension

Galie, 2009, Guidelines for the diagnosis and treatment of pulmonary hypertension, Eur Heart J, 30, 2493, 10.1093/eurheartj/ehp297 Hoeper, 2013, Definitions and diagnosis of pulmonary hypertension, J Am Coll Cardiol, 62, D42, 10.1016/j.jacc.2013.10.032 Schermuly, 2011, Mechanisms of disease: pulmonary arterial hypertension, Nat Rev Cardiol, 8, 443, 10.1038/nrcardio.2011.87 Tuder, 2013, Relevant issues in the pathology and pathobiology of pulmonary hypertension, J Am Coll Cardiol, 62, D4, 10.1016/j.jacc.2013.10.025 Galie, 2005, Sildenafil citrate therapy for pulmonary arterial hypertension, N Engl J Med, 353, 2148, 10.1056/NEJMoa050010 Ghofrani, 2006, Sildenafil: From angina to erectile dysfunction to pulmonary hypertension and beyond, Nat Rev Drug Discov, 5, 689, 10.1038/nrd2030 Wilkins, 2008, Phosphodiesterase inhibitors for the treatment of pulmonary hypertension, Eur Respir J, 32, 198, 10.1183/09031936.00124007 McLaughlin, 2013, Treatment goals of pulmonary hypertension, J Am Coll Cardiol, 62, D73, 10.1016/j.jacc.2013.10.034 Galie, 2013, Updated treatment algorithm of pulmonary arterial hypertension, J Am Coll Cardiol, 62, D60, 10.1016/j.jacc.2013.10.031 Sastry, 2004, Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study, J Am Coll Cardiol, 43, 1149, 10.1016/j.jacc.2003.10.056 Singh, 2006, A randomized, placebo-controlled, double-blind, crossover study to evaluate the efficacy of oral sildenafil therapy in severe pulmonary artery hypertension, Am Heart J, 151, 851.e1, 10.1016/j.ahj.2005.09.006 Rubin, 2011, Long-term treatment with sildenafil citrate in pulmonary arterial hypertension-the super-2 study, Chest, 140, 1274, 10.1378/chest.10-0969 Ichinose, 2001, Nebulized sildenafil is a selective pulmonary vasodilator in lambs with acute pulmonary hypertension, Crit Care Med, 29, 1000, 10.1097/00003246-200105000-00024 Olschewski, 2002, Inhaled iloprost for severe pulmonary hypertension, N Engl J Med, 347, 322, 10.1056/NEJMoa020204 Gessler, 2008, Inhaled prostanoids in the therapy of pulmonary hypertension, J Aerosol Med, 21, 1, 10.1089/jamp.2007.0657 Farokhzad, 2009, Impact of nanotechnology on drug delivery, ACS Nano, 3, 16, 10.1021/nn900002m Shi, 2010, Nanotechnology in drug delivery and tissue engineering: from discovery to application, Nano Lett, 10, 3223, 10.1021/nl102184c Beck-Broichsitter, 2012, Controlled pulmonary drug and gene delivery using polymeric nano-carriers, J Control Release, 161, 214, 10.1016/j.jconrel.2011.12.004 Beck-Broichsitter, 2010, Pulmonary targeting with biodegradable salbutamol-loaded nanoparticles, J Aerosol Med, 23, 47, 10.1089/jamp.2009.0759 Rytting, 2010, In vitro and in vivo performance of biocompatible negatively-charged salbutamol-loaded nanoparticles, J Control Release, 141, 101, 10.1016/j.jconrel.2009.08.021 Trivedi, 2012, Local delivery of biodegradable pirfenidone nanoparticles ameliorates bleomycin-induced pulmonary fibrosis in mice, Nanotechnology, 23, 505101, 10.1088/0957-4484/23/50/505101 Roa, 2011, Inhalable nanoparticles, a non-invasive approach to treat lung cancer in a mouse model, J Control Release, 150, 49, 10.1016/j.jconrel.2010.10.035 Beck-Broichsitter, 2012, Nebulization performance of biodegradable sildenafil-loaded nanoparticles using the Aeroneb® pro: formulation aspects and nanoparticle stability to nebulization, Int J Pharm, 422, 398, 10.1016/j.ijpharm.2011.10.012 Beck-Broichsitter, 2012, Development of a biodegradable nanoparticle platform for sildenafil: formulation optimization by factorial design analysis combined with application of charge-modified branched polyesters, J Control Release, 157, 469, 10.1016/j.jconrel.2011.09.058 Beck-Broichsitter, 2012, Characterization of novel spray-dried polymeric particles for controlled pulmonary drug delivery, J Control Release, 158, 329, 10.1016/j.jconrel.2011.10.030 Loira-Pastoriza, 2014, Delivery strategies for sustained drug release in the lungs, Adv Drug Deliv Rev, 75, 81, 10.1016/j.addr.2014.05.017 Wang, 2008, Biodegradable branched polyesters poly(vinyl sulfonate-co-vinyl alcohol)-graft-poly(d, l-lactic-co-glycolic acid) as a negatively charged electrolyte platform for drug delivery: synthesis and characterization, Macromolecules, 41, 2791, 10.1021/ma702705s Schermuly, 1999, Low-dose systemic phosphodiesterase inhibitors amplify the pulmonary vasodilatory response to inhaled prostacyclin in experimental pulmonary hypertension, Am J Respir Crit Care Med, 160, 1500, 10.1164/ajrccm.160.5.9901102 Schermuly, 2001, Coaerosolization of phosphodiesterase inhibitors markedly enhances the pulmonary vasodilatory response to inhaled iloprost in experimental pulmonary hypertension. Maintenance of lung selectivity, Am J Respir Crit Care Med, 164, 1694, 10.1164/ajrccm.164.9.2105060 Schermuly, 2001, Urodilatin, a natriuretic peptide stimulating particulate guanylate cyclase, and the phosphodiesterase 5 inhibitor dipyridamole attenuate experimental pulmonary hypertension: synergism upon coapplication, Am J Respir Cell Mol Biol, 25, 219, 10.1165/ajrcmb.25.2.4256 Schermuly, 2005, Lung vasodilatory response to inhaled iloprost in experimental pulmonary hypertension: amplification by different type of phosphodiesterase inhibitors, Respir Res, 6, 76, 10.1186/1465-9921-6-76 Bradford, 1976, A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding, Anal Biochem, 72, 248, 10.1016/0003-2697(76)90527-3 Schmidt, 2004, Changes in pulmonary surfactant function and composition in bleomycin-induced pneumonitis and fibrosis, Toxicol Appl Pharmacol, 195, 218, 10.1016/j.taap.2003.11.011 Dailey, 2006, Investigation of the proinflammatory potential of biodegradable nanoparticle drug delivery systems in the lung, Toxicol Appl Pharmacol, 215, 100, 10.1016/j.taap.2006.01.016 Ghofrani, 2004, Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study, J Am Coll Cardiol, 44, 1488 Pullamsetti, 2014, Novel and emerging therapies for pulmonary hypertension, Am J Respir Crit Care Med, 189, 394, 10.1164/rccm.201308-1543PP Fattal, 2014, Lung toxicity of biodegradable nanoparticles, J Biomed Nanotechnol, 10, 2852, 10.1166/jbn.2014.1939 Jones, 2014, Quantitative assessment of nanoparticle surface hydrophobicity and its influence on pulmonary biocompatibility, J Control Release, 183, 94, 10.1016/j.jconrel.2014.03.022